CSBR director exercises 94,405 options at $2.1; holds 1,056,539

Champions Oncology (CSBR) director Joel Ackerman reported an insider transaction on Form 4.

Rhea-AI Filing Summary

Champions Oncology (CSBR) director Joel Ackerman reported an insider transaction on Form 4. On 10/30/2025, he exercised stock options for 94,405 shares at $2.1 per share (transaction code M), acquiring the same number of common shares.

After the transaction, he reported 1,056,539 shares beneficially owned directly and 0 derivative securities remaining. The exercised option covered 94,405 underlying shares with a $2.1 exercise price.

Insider Trade Summary

94,405 shares exercised/converted

Exercise 2 txns

Insider ACKERMAN JOEL

Role Director

Type	Security	Shares	Price	Value
Exercise	Option to purchase Common Stock	94,405	$2.10	$198K
Exercise	Common Stock	94,405	$2.10	$198K

Holdings After Transaction: Option to purchase Common Stock — 0 contracts (Direct); Common Stock — 1,056,539 shares (Direct)

Footnotes (1)

1. F1. 70,804 options were immediately exercisable on grant date of July 19, 2016, with the remaining options vesting and available to exercise on October 31, 2016.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CSBR report?

A director exercised options for 94,405 shares at $2.1 per share, acquiring the same number of common shares on 10/30/2025.

How many CSBR shares does the insider own after the transaction?

He reported 1,056,539 shares beneficially owned directly following the transaction.

What was the exercise price and size of the option for CSBR?

The option covered 94,405 underlying shares with a $2.1 exercise price.

What was the Form 4 transaction code for CSBR?

The filing lists transaction code M, indicating an option exercise.

Does the CSBR insider hold any derivative securities after the exercise?

No. The filing shows 0 derivative securities beneficially owned after the reported transaction.

What is the insider’s relationship to CSBR?

The reporting person is a Director of Champions Oncology, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 11:19 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ACKERMAN JOEL

(Last) (First) (Middle)

C/O CHAMPIONS ONCOLOGY, INC.

ONE UNIVERSITY PLACE, SUITE 307

(Street)

HACKENSACK NJ 07601

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		M		94,405	A	$2.1	1,056,539	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	$2.1	10/30/2025		M			94,405	(1)	11/01/2025	Common Stock	94,405	$2.1	0	D

Explanation of Responses:

1. 70,804 options were immediately exercisable on grant date of July 19, 2016, with the remaining options vesting and available to exercise on October 31, 2016.

Remarks:

	/s/ Joel Ackerman	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.